Pandora (NYSE:P) was lower nearly 4% in recent pre-market trade even as it reported that listener hours on its internet radio service rose 9% to 1.51 billion in February. The number of active listeners rose 11% to 75.3 million. Pandora (NYSE:P) said it plans to discontinue monthly disclosure of key audience metrics after a final monthly…
Rock-Tenn Company (NYSE:RKT), an integrated manufacturer of corrugated and consumer packaging, has agreed to acquire the Simpson Tacoma Kraft Paper Mill located in Tacoma, Wash., for approximately $343 million. The transaction is structured as an asset purchase. Rock-Tenn Company (NYSE:RKT) has committed to invest $60 million in the mill during the next three years and…
Cooper Tire & Rubber (NYSE:CTB) is down 8.2% to $22.79 per share after Q3 results showed a $29 million reduction in operating profit due to July/August work stoppages at the CCT joint venture and manufacturing inefficiencies. The company reported a Q3 net loss of $168,000 in Q3 compared to a net profit of $74 million…
Shares of Dendreon (NASDAQ:DNDN) gained 16% in late morning trade Monday as investors responded enthusiastically to the biotechnology company’s Q4 results and its announcement it will make its Provenge prostate-cancer treatment commercially available in Germany and the U.K. The company reported a narrower-than-expected Q4 adjusted loss on revenue that was above Street estimates and saw…
xG Technology, Inc. (NASDAQ:XGTI), a developer of wireless communications and spectrum sharing technologies, has been awarded a U.S. Patent for cognitive radio that will enable high-performance spectrum sharing. This patent, “Measurement Coordination for Dynamic Spectrum Access Measurements in a Time Division Duplex System”, is an important part of xG Technology, Inc. (NASDAQ:XGTI)’s Dynamic Spectrum Access…
Array BioPharma (NASDAQ:ARRY) was up more than 9% in pre-market trade after reporting positive study results for its asthma treatment. The company said, ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in…
